Combined chemokine and cytokine gene transfer enhances antitumor immunity

Nature Medicine

Volumn 2, Issue 10, 1996, Pages 1090-1095

  Dilloo, Dagmar ^a   Bacon, Kevin ^b   Holden, William ^a   Zhong, Wanyun ^a   Burdach, Stefan ^c   Zlotnik, Albert ^b   Brenner, Malcolm ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; INTERLEUKIN 2; LYMPHOTACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, C; CHEMOTAXIS, LEUKOCYTE; FEMALE; FIBROBLASTS; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOKINES; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SIALOGLYCOPROTEINS;

ANIMALIA; MURINAE;

EID: 0029845753     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1096-1090     Document Type: Article

References (38)

1. Nabel, G.J. et al. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90, 11307-11311 (1993).
2. Foreman, N.K. et al. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells: Potential for residual disease eradication. Br. J. Cancer 67, 933-938 (1993).
3. Gansbacher, B. et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224 (1990).
4. Golumbek, P.T. et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716 (1991).
5. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539 (1993).
6. Guinan, E.C. et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-3282 (1994).
7. Tahara, H. et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54, 182-189 (1994).
8. Fearon, E.R. et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403 (1990).
9. Asher, A.L. et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146, 3227-3234 (1991).
10. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629 (1995).
11. Matulonis, U.A. et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85, 2507-2515 (1995).
12. Chen, L. et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102 (1992).
13. Schwartz, R.H. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1068 (1992).
14. Kelner, G.S. et al. Lymphotactin: A cytokine that represents a new class of chemokine. Science 266, 1395 (1994).
15. Kennedy, J. et al. Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 155, 203-209 (1995).
16. Schmidt, W. et al. Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711-4714 (1995).
17. Russell, S.J. et al. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of IL-2 cDNA. Int. J. Cancer 47, 244-251 (1991).
18. Fakhrai, H. et al. Cytokine gene therapy with interleukin-2 transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. 6, 591-601 (1995).
19. Maass, G. et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 92, 5540-5544 (1995).
20. Kim, K.J. et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122, 549-554 (1979).
21. Glimcher, L.H., Kim, K., Green, I. & Paul, W.E. Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J. Exp. Med. 155, 445-459 (1982).
22. Armstrong, C.A. et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56, 2191-2198 (1996).
23. Oppenheim, J.J., Zachariae, C.O., Mukaida, N. & Matsushima, K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol. 9, 617 (1991).
24. Schell, T. The chemokines. in The Cytokine Handbook. (Thomson, A., ed.) 419-460 (Academic Press, New York, 1994).
25. Karp, S.E. et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J. Immunol. 150, 896-908 (1993).
26. Maraninchi, D. et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78, 2182-2187 (1991).
27. Meloni, G. et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84, 2158-2163 (1994).
28. Wakimoto, H. et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin-4. Cancer Res. 56, 1828-1833 (1996).
29. Patek, P.Q., Collins, J.L. & Cohn, M. Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature 276, 510-511 (1978).
30. Spencer, H.T. et al. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood (in the press).
31. Pear, W.S., Nolan, G.P., Scott, M.L. & Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392-8396 (1993).
32. Hogge, D.E., Cashman, J.D., Humphries, R.K. & Eaves, C.J. Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow cultures. Blood 77, 493-499 (1991).
33. Brenner, M.K. et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342, 1134-1137 (1993).
34. Bender, M.A., Palmer, T.D., Gelinas, R.E. & Miller, A.D. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J. Virol. 61, 1639-1646 (1987).
35. Bacon, K.B., Camp, R.D., Cunningham, F.M. & Woollard, P.M. Contrasting in vitro lymphocyte chemotactic activity of the hydroxy enantiomers of 12-hydroxy-5,8,10,14-eicosatetraenoic acid. Br. J. Pharmacol. 95, 966-974 (1988).
36. Dialynas, D.P. et al. Characterization of the murine T-cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131, 2445-2451 (1983).
37. Sarmiento, M., Glasebrook, A.L. & Fitch, F.W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125, 2665-2672 (1980).
38. Li, C.Y., Ziesmer, S.C. & Yam, L.T. Practical immunocytochemical identification of human blood cells. Am. J. Clin. Pathol. 81, 204 (1984).